Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P, Shaughnessy L, VanLunen B, van der Heijde D. Keystone E, et al. Among authors: vanlunen b. Ann Rheum Dis. 2014 Dec;73(12):2094-100. doi: 10.1136/annrheumdis-2013-203695. Epub 2013 Aug 5. Ann Rheum Dis. 2014. PMID: 23918037 Free PMC article. Clinical Trial.
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME. Emery P, et al. Among authors: vanlunen b. Ann Rheum Dis. 2017 Jan;76(1):96-104. doi: 10.1136/annrheumdis-2015-209057. Epub 2016 May 10. Ann Rheum Dis. 2017. PMID: 27165179 Free PMC article. Clinical Trial.
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.
Weinblatt ME, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P. Weinblatt ME, et al. Among authors: vanlunen b. Arthritis Rheumatol. 2017 Oct;69(10):1937-1948. doi: 10.1002/art.40196. Epub 2017 Sep 12. Arthritis Rheumatol. 2017. PMID: 28666080 Free PMC article. Clinical Trial.
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.
Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, Heijde Dv, Vollenhoven Rv, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME. Emery P, et al. Among authors: vanlunen b. Ann Rheum Dis. 2016 Oct;75(10):e69. doi: 10.1136/annrheumdis-2016-210083. Epub 2016 Aug 12. Ann Rheum Dis. 2016. PMID: 27519773 Free article. No abstract available.
Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
Baraliakos X, Witte T, De Clerck L, Frediani B, Collantes-Estévez E, Katsifis G, VanLunen B, Kleine E, Hoepken B, Bauer L, Goodson N. Baraliakos X, et al. Among authors: vanlunen b. Rheumatology (Oxford). 2021 Jan 5;60(1):113-124. doi: 10.1093/rheumatology/keaa181. Rheumatology (Oxford). 2021. PMID: 32584415 Free PMC article.
The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
van der Horst-Bruinsma I, van Bentum R, Verbraak FD, Rath T, Rosenbaum JT, Misterska-Skora M, Hoepken B, Irvin-Sellers O, VanLunen B, Bauer L, Rudwaleit M. van der Horst-Bruinsma I, et al. Among authors: vanlunen b. RMD Open. 2020 Apr;6(1):e001161. doi: 10.1136/rmdopen-2019-001161. RMD Open. 2020. PMID: 32371433 Free PMC article. Clinical Trial.
13 results